| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
4 allele is associated with cognitive impairment in patients with multiple sclerosis
From the Division of Neurology (J.S., C.Z., T.L.V., T.M.T.), Barrow Neurological Institute, St. Joseph’s Hospital and Medical Center, Phoenix, AZ; and Department of Neurology (S.M.K.), University of Texas Medical Branch, Galveston.
* To whom correspondence should be addressed. E-mail: jiong.shi{at}chw.edu.
Abstract Background: The role of apolipoprotein E (APOE) polymorphism has been well recognized in other cognitive neurodegenerative disorders, such as Alzheimer disease. Its role in multiple sclerosis (MS) is less clear, though studies indicate that 40% to 60% of patients with MS have evidence of cognitive impairment. Objective: To determine whether there is an association between APOE 
4 and cognitive deficits in MS. Methods: We performed a standardized battery of neuropsychological tests investigating the four cognitive domains commonly impaired in MS and assessed the association of the presence of APOE 4 with cognition in MS. Results: A strong association was found between the presence of APOE 4 and cognitive deficits in patients with MS, particularly in the domains of learning and memory. This association was strongest in our youngest cohort (age 31 to 40) of patients with MS. Conclusions: APOE 4 is significantly associated with cognitive impairment in patients with multiple sclerosis (MS). However, the modest effects do not justify APOE genotyping of patients with MS in clinical practice.
This article has been cited by other articles:
|
|
 |
|
  A. van der Walt, J. Stankovich, M. Bahlo, B. V. Taylor, I.A.F. van der Mei, S. J. Foote, T. J. Kilpatrick, J. P. Rubio, and H. Butzkueven Apolipoprotein genotype does not influence MS severity, cognition, or brain atrophy Neurology, September 29, 2009; 73(13): 1018 - 1025. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Julian, L Vella, D Frankel, S. Minden, J. Oksenberg, and D. Mohr ApoE alleles, depression and positive affect in multiple sclerosis Multiple Sclerosis, March 1, 2009; 15(3): 311 - 315. [Abstract] [PDF]
|
|
|
|
|
|
G Koutsis, M Panas, E Giogkaraki, G Karadima, C Sfagos, and D Vassilopoulos An APOA1 promoter polymorphism is associated with cognitive performance in patients with multiple sclerosis Multiple Sclerosis, February 1, 2009; 15(2): 174 - 179. [Abstract] [PDF]
|
|
|
|
|
|
A. A. Mazurek and J. Shi APOE {varepsilon}4 ALLELE IS ASSOCIATED WITH COGNITIVE IMPAIRMENT IN PATIENTS WITH MULTIPLE SCLEROSIS Neurology, October 7, 2008; 71(15): 1203 - 1203. [Full Text] [PDF]
|
|
|
|
 |
|
 Disease Mechanisms in Neuroscience Neuroscientist, June 1, 2008; 14(3): 234 - 234. [PDF]
|
|
|
|
|
|
A. D. Sadovnick and D. H. Jacobs MS and cognition and APOE: The ongoing conundrum about biomarkers Neurology, January 15, 2008; 70(3): 164 - 165. [Full Text] [PDF]
|
|
Read all Correspondence
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
